Clinical Benefit of Low Molecular Weight Heparin for ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention with Glycoprotein IIb/IIIa Inhibitor.
10.3346/jkms.2010.25.11.1601
- Author:
Jung Sun CHO
1
;
Sung Ho HER
;
Ju Yeal BAEK
;
Mahn Won PARK
;
Hyoung Doo KIM
;
Myung Ho JEONG
;
Young keun AHN
;
Shung Chull CHAE
;
Seung Ho HUR
;
Taek Jong HONG
;
Young Jo KIM
;
In Whan SEONG
;
Jei Keon CHAE
;
Jay Young RHEW
;
In Ho CHAE
;
Myeong Chan CHO
;
Jang Ho BAE
;
Seung Woon RHA
;
Chong Jim KIM
;
Donghoon CHOI
;
Yang Soo JANG
;
Junghan YOON
;
Wook Sung CHUNG
;
Jeong Gwan CHO
;
Ki Bae SEUNG
;
Seung Jung PARK
Author Information
1. Cardiovascular Center, Seoul St. Mary's Hospital, Seoul, Korea.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Myocardial Infarction;
Heparin;
Blood Platelets;
Prognosis
- MeSH:
Acute Disease;
Aged;
Drug Therapy, Combination;
Female;
Hemorrhage;
Heparin/*therapeutic use;
Heparin, Low-Molecular-Weight/*therapeutic use;
Humans;
Male;
Middle Aged;
Multivariate Analysis;
Myocardial Infarction/epidemiology/mortality/*therapy;
Myocardial Revascularization;
Odds Ratio;
Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors/metabolism;
Prognosis;
Registries
- From:Journal of Korean Medical Science
2010;25(11):1601-1608
- CountryRepublic of Korea
- Language:English
-
Abstract:
The efficacy of low molecular weight heparin (LMWH) with low dose unfractionated heparin (UFH) during percutaneous coronary intervention (PCI) with or without glycoprotein (Gp) IIb/IIIa inhibitor compared to UFH with or without Gp IIb/IIIa inhibitor has not been elucidated. Between October 2005 and July 2007, 2,535 patients with ST elevation acute myocardial infarction (STEMI) undergoing PCI in the Korean Acute Myocardial Infarction Registry (KAMIR) were assigned to either of two groups: a group with Gp IIb/IIIa inhibitor (n=476) or a group without Gp IIb/IIIa inhibitor (n=2,059). These groups were further subdivided according to the use of LMWH with low dose UFH (n=219) or UFH alone (n=257). The primary end points were cardiac death or myocardial infarction during the 30 days after the registration. The primary end point occurred in 4.1% (9/219) of patients managed with LMWH during PCI and Gp IIb/IIIa inhibitor and 10.8% (28/257) of patients managed with UFH and Gp IIb/IIIa inhibitor (odds ratio [OR], 0.290; 95% confidence interval [CI], 0.132-0.634; P=0.006). Thrombolysis In Myocardial Infarction (TIMI) with major bleeding was observed in LMHW and UFH with Gp IIb/IIIa inhibitor (1/219 [0.5%] vs 1/257 [0.4%], P=1.00). For patients with STEMI managed with a primary PCI and Gp IIb/IIIa inhibitor, LMWH is more beneficial than UFH.
